Alnylam Pharmaceuticals (ALNY) risk factors
Item 1A of every Alnylam Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors54 risks11 new13 dropped21 reworded
Alnylam achieved profitability in fiscal 2025, driven heavily by $2.99 billion in product revenues from AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Filed Feb 12, 2026 - FY2024 10-K risk factors56 risks
Alnylam faces substantial financial risks with an accumulated deficit of $7.29 billion as of December 31, 2024. The company relies heavily on commercial success for AMVUTTRA and royalties from Leqvio. Operations depend on third-party manufacturing, clinical trial execution, and complex global intellectual property licensing. Regulatory pricing pressures and compliance across international jurisdictions present ongoing challenges.
Filed Feb 13, 2025